Innovent Biologics (HK:1801) has released an update.
Innovent Biologics announces the Chinese National Medical Products Administration’s acceptance of their New Drug Application for IBI311, an antibody treatment for thyroid eye disease (TED). The NDA is supported by positive results from the Phase 3 RESTORE-1 clinical study, indicating significant improvements in patients and a favorable safety profile. This breakthrough could provide an effective and accessible treatment for TED in China, where such options have been lacking.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
